Is SPRY or HELP more profitable?

Cybin has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Cybin's return on equity of -59.98% beat ARS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals -200.00% -153.61% -60.85% Cybin N/A -59.98% -50.80%

Does the media favor SPRY or HELP?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Cybin. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 6 mentions for Cybin. Cybin's average media sentiment score of 0.37 beat ARS Pharmaceuticals' score of 0.12 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, CRON or HELP?

Cronos Group has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group $146.59M 7.06 -$9.45M $0.01 277.50 Cybin N/A N/A -$81.31M -$4.23 N/A

Is CRON or HELP more profitable?

Cybin has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cronos Group -1.14% -1.26% -1.20% Cybin N/A -59.98% -50.80%

Does the media prefer CRON or HELP?

In the previous week, Cybin had 3 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Cybin and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.26 beat Cybin's score of 0.37 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, HELP or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A Jade Biosciences N/A N/A -$127.41M -$2.02 N/A

Is HELP or JBIO more profitable?

Jade Biosciences' return on equity of -51.34% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Jade Biosciences N/A -51.34% -47.32%

Does the media prefer HELP or JBIO?

In the previous week, Cybin had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Cybin and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.93 beat Cybin's score of 0.37 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, BIOA or HELP?

BioAge Labs has higher revenue and earnings than Cybin. BioAge Labs is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAge Labs $10.32M 101.23 -$80.61M -$2.40 N/A Cybin N/A N/A -$81.31M -$4.23 N/A

Is BIOA or HELP more profitable?

Cybin has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets BioAge Labs -871.75% -29.40% -27.26% Cybin N/A -59.98% -50.80%

Does the media prefer BIOA or HELP?

In the previous week, Cybin had 2 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Cybin and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.47 beat Cybin's score of 0.37 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, HELP or SANA?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cybin N/A N/A -$81.31M -$4.23 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is HELP or SANA more profitable?

Cybin's return on equity of -59.98% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -59.98% -50.80% Sana Biotechnology N/A -108.01% -40.68%

Cybin (HELP) Competitors

$6.52 +0.50 (+8.24%)

As of 11:46 AM Eastern

Compare

HELP vs. SPRY, CRON, JBIO, BIOA, and SANA

Should you buy Cybin stock or one of its competitors? MarketBeat compares Cybin with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cybin include ARS Pharmaceuticals (SPRY), Cronos Group (CRON), Jade Biosciences (JBIO), BioAge Labs (BIOA), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does Cybin compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Cybin has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Cybin's return on equity of -59.98% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Cybin	N/A	-59.98%	-50.80%

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Cybin. MarketBeat recorded 10 mentions for ARS Pharmaceuticals and 6 mentions for Cybin. Cybin's average media sentiment score of 0.37 beat ARS Pharmaceuticals' score of 0.12 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cybin has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.98	-$171.30M	-$2.01	N/A
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ARS Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Cybin has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

ARS Pharmaceuticals currently has a consensus price target of $28.20, indicating a potential upside of 233.06%. Cybin has a consensus price target of $58.75, indicating a potential upside of 801.63%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Cybin beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Cronos Group has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	7.06	-$9.45M	$0.01	277.50
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A

Cronos Group presently has a consensus price target of $2.30, suggesting a potential downside of 17.12%. Cybin has a consensus price target of $58.75, suggesting a potential upside of 801.63%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cybin has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
Cybin	N/A	-59.98%	-50.80%

In the previous week, Cybin had 3 more articles in the media than Cronos Group. MarketBeat recorded 6 mentions for Cybin and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.26 beat Cybin's score of 0.37 indicating that Cronos Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cronos Group has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Cybin has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

Cronos Group beats Cybin on 8 of the 15 factors compared between the two stocks.

How does Cybin compare to Jade Biosciences?

Cybin (NASDAQ:HELP) and Jade Biosciences (NASDAQ:JBIO) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Cybin currently has a consensus price target of $58.75, indicating a potential upside of 801.63%. Jade Biosciences has a consensus price target of $47.13, indicating a potential upside of 117.77%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cybin is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cybin had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 6 mentions for Cybin and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.93 beat Cybin's score of 0.37 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences' return on equity of -51.34% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Jade Biosciences	N/A	-51.34%	-47.32%

Jade Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Cybin has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Summary

Jade Biosciences beats Cybin on 8 of the 14 factors compared between the two stocks.

How does Cybin compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Cybin (NASDAQ:HELP) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

BioAge Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Cybin has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

BioAge Labs has higher revenue and earnings than Cybin. BioAge Labs is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	101.23	-$80.61M	-$2.40	N/A
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A

17.9% of Cybin shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cybin had 2 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Cybin and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.47 beat Cybin's score of 0.37 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cybin has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Cybin	N/A	-59.98%	-50.80%

BioAge Labs presently has a consensus price target of $43.50, suggesting a potential upside of 85.18%. Cybin has a consensus price target of $58.75, suggesting a potential upside of 801.63%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

BioAge Labs beats Cybin on 9 of the 15 factors compared between the two stocks.

How does Cybin compare to Sana Biotechnology?

Cybin (NASDAQ:HELP) and Sana Biotechnology (NASDAQ:SANA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

In the previous week, Cybin had 5 more articles in the media than Sana Biotechnology. MarketBeat recorded 6 mentions for Cybin and 1 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.87 beat Cybin's score of 0.37 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cybin	Neutral
Sana Biotechnology	Very Positive

Cybin's return on equity of -59.98% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
Sana Biotechnology	N/A	-108.01%	-40.68%

17.9% of Cybin shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sana Biotechnology is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Cybin has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market.

Cybin currently has a consensus target price of $58.75, indicating a potential upside of 801.63%. Sana Biotechnology has a consensus target price of $9.50, indicating a potential upside of 171.82%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Sana Biotechnology beats Cybin on 7 of the 13 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$334.83M	$2.94B	$4.34B	$12.17B
Dividend Yield	N/A	15.31%	11.51%	5.90%
P/E Ratio	-1.53	13.52	22.00	24.04
Price / Sales	N/A	2,975.17	206.55	100.34
Price / Cash	N/A	26.03	38.01	53.91
Price / Book	0.83	4.85	13.63	6.34
Net Income	-$81.31M	-$34.85M	$115.37M	$337.43M
7 Day Performance	39.53%	-1.20%	-1.26%	-0.63%
1 Month Performance	47.09%	-1.61%	-2.54%	-0.07%
1 Year Performance	N/A	12.13%	11.24%	26.35%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	2.7327 of 5 stars	$6.52 +8.2%	$58.75 +801.6%	N/A	$334.83M	N/A	N/A	50	News Coverage
SPRY ARS Pharmaceuticals	3.4104 of 5 stars	$10.28 +3.0%	$28.60 +178.2%	-53.5%	$991.05M	$84.28M	N/A	90	News Coverage Analyst Forecast
CRON Cronos Group	1.3138 of 5 stars	$2.70 +1.9%	$2.30 -14.8%	+44.4%	$988.54M	$146.59M	270.27	450	Positive News
JBIO Jade Biosciences	2.325 of 5 stars	$21.86 +12.4%	$47.13 +115.6%	+107.5%	$960.05M	N/A	N/A	20
BIOA BioAge Labs	2.5703 of 5 stars	$22.32 +4.0%	$43.50 +94.9%	N/A	$954.40M	$8.99M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. SPRY, CRON, JBIO, BIOA, and SANA

How does Cybin compare to ARS Pharmaceuticals?

Summary

How does Cybin compare to Cronos Group?

Summary

How does Cybin compare to Jade Biosciences?

Summary

How does Cybin compare to BioAge Labs?

Summary

How does Cybin compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. SPRY, CRON, JBIO, BIOA, and SANA

How does Cybin compare to ARS Pharmaceuticals?

Is SPRY or HELP more profitable?

Does the media favor SPRY or HELP?

Which has stronger valuation & earnings, SPRY or HELP?

Do insiders & institutionals believe in SPRY or HELP?

Which has more risk and volatility, SPRY or HELP?

Do analysts recommend SPRY or HELP?

Summary

How does Cybin compare to Cronos Group?

Which has preferable valuation & earnings, CRON or HELP?

Do analysts recommend CRON or HELP?

Is CRON or HELP more profitable?

Does the media prefer CRON or HELP?

Do insiders and institutionals hold more shares of CRON or HELP?

Which has more risk & volatility, CRON or HELP?

Summary

How does Cybin compare to Jade Biosciences?

Do analysts rate HELP or JBIO?

Do institutionals & insiders believe in HELP or JBIO?

Does the media prefer HELP or JBIO?

Is HELP or JBIO more profitable?

Which has preferable earnings and valuation, HELP or JBIO?

Which has more volatility and risk, HELP or JBIO?

Summary

How does Cybin compare to BioAge Labs?

Which has more volatility and risk, BIOA or HELP?

Which has preferable earnings & valuation, BIOA or HELP?

Do insiders & institutionals hold more shares of BIOA or HELP?

Does the media prefer BIOA or HELP?

Is BIOA or HELP more profitable?

Do analysts rate BIOA or HELP?

Summary

How does Cybin compare to Sana Biotechnology?

Does the media refer more to HELP or SANA?

Is HELP or SANA more profitable?

Do insiders & institutionals have more ownership in HELP or SANA?

Which has preferable valuation and earnings, HELP or SANA?

Which has more volatility & risk, HELP or SANA?

Do analysts prefer HELP or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools